Cannara Biotech (TSXV:LOVE) COGS-to-Revenue : 0.55 (As of Feb. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech COGS-to-Revenue?

Cannara Biotech's Cost of Goods Sold for the three months ended in Feb. 2025 was C$14.63 Mil. Its Revenue for the three months ended in Feb. 2025 was C$26.59 Mil.

Cannara Biotech's COGS to Revenue for the three months ended in Feb. 2025 was 0.55.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cannara Biotech's Gross Margin % for the three months ended in Feb. 2025 was 44.97%.

Cannara Biotech COGS-to-Revenue Historical Data

The historical data trend for Cannara Biotech's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech COGS-to-Revenue Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

COGS-to-Revenue

Get a 7-Day Free Trial

0.52

0.40

0.52

0.64

Cannara Biotech Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
COGS-to-Revenue	Get a 7-Day Free Trial															0.79	0.64	0.55	0.59	0.55

Cannara Biotech COGS-to-Revenue Calculation

Cannara Biotech's COGS to Revenue for the fiscal year that ended in Aug. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	51.961	/	81.748
	=	0.64

Cannara Biotech's COGS to Revenue for the quarter that ended in Feb. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	14.63	/	26.586
	=	0.55

Cannara Biotech (TSXV:LOVE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cannara Biotech's Gross Margin % for the three months ended in Feb. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	14.63 / 26.586
	=	44.97 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cannara Biotech COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

LOVFF:USA 8CB0:Germany

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Executives

Olymbec Investments Inc.	10% Security Holder
Nicholas Sosiak	Senior Officer
Donald John Olds	Director
Derek Elan Stern	Director
Scott Carroll	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Zohar Krivorot	Director, Senior Officer
Brian Sherman	Senior Officer
Avi Krivorot	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Lennie Ryer	Senior Officer
Jack M. Kay	Director
Donal Carroll	Director or Senior Officer of 10% Security Holder